Carrera Capital Advisors Sells 5,260 Shares of Stryker Corporation $SYK

Carrera Capital Advisors cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 68.8% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 2,381 shares of the medical technology company’s stock after selling 5,260 shares during the quarter. Carrera Capital Advisors’ holdings in Stryker were worth $752,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of SYK. Godfrey Financial Associates Inc. purchased a new stake in Stryker in the fourth quarter worth approximately $26,000. Sankala Group LLC bought a new position in shares of Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the fourth quarter worth $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker during the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $338.80 on Friday. The stock has a market cap of $129.95 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm has a fifty day moving average price of $324.61 and a 200-day moving average price of $333.57. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SYK. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday. Truist Financial raised their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Canaccord Genuity Group reduced their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Argus set a $370.00 price target on shares of Stryker in a research note on Thursday, July 9th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.